In breast cancer, febrile neutropenia-related admissions account for significant mortality
the ONA take:
According to a new study published in the journal Supportive Care in Cancer, researchers from the Reading Health System Department of Internal Medicine in West Reading, Pennsylvania, have found that febrile neutropenia-related hospitalizations still account for significant health care resource use, morbidity, and mortality among patients with breast cancer.
For the retrospective study, researchers sought to investigate the mean length of stay, incidence of morbidity and mortality, and health care costs associated with febrile neutropenia-related admissions of patients with breast cancer.
Researchers identified patients with breast cancer who were hospitalized for febrile neutropenia between 2009 and 2011 from the Nationwide Impact Sample database. Results showed that the mean length of stay was 5.7 days (95% CI: 5.5 - 5.9) and the mean cost of hospitalization was $37,087 (95% CI: 34,009 - 40,165).
They found that the average inhospital mortality rate during that period was 2.6% (n = 685), and age 65 years and older was associated with a higher risk of mortality (4.4% vs 1.7%; OR = 2.7; 95% CI: 2.3 - 3.1; P < 0.01). The findings suggest that febrile neutropenia accounts for significant mortality, and more effort needs to be made to reduce the cost of health care without decreasing the quality of care.
Febrile neutropenia-related hospitalizations still account for morbidity, and mortality among patients with breast cancer.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|